by Müller S, Ackloo S, Chawaf AA, Al-Lazikani B, Antolin A, Baell JB, Beck H, Beedie S, Betz UAK, Bezerra GA,k Brennan PE, Brown D, Brown PJ, Bullock AN, Carter AJ, Chaikuad A, Chaineau M, Ciulli A, Collins I, Dreher J, Drewry D, Edfeldt K, Edwards AM, Egner U, Frye SV, Fuchs SM, Hall MD, Hartung IV, Hillisch A, Hitchcock SH, Homan E, Kannan N, Kiefer JR, Knapp S, Kostic M, Kubicek S, Leach AR, Lindemann S, Marsden BD, Matsui H, Meier JL, Merk D, Michel M, Morgan MR, Mueller-Fahrnow A, Owen DR, Perry BG, Rosenberg SH, Saikatendu KS, Schapira M, Scholten C, Sharma S, Simeonov A, Sundström M, Superti-Furga G, Todd MH, Tredup C, Vedadi M, von Delft F, Willson TM, Winter GE, Workman P, Arrowsmith CH. RSC Medicinal Chemistry 2022;13, 13-21. doi: 10.1039/D1MD00228G
Summary: Twenty years after the publication of the first draft of the human genome, our knowledge of it remains fragmented. A large proportion of proteins in the human proteome (∼35%) remain uncharacterized, and less than 5% of the human proteome has been successfully targeted for drug discovery. This highlights the profound disconnect between our abilities to obtain genetic information and subsequent development of effective medicines. The authors provide an update on progress in establishing Phase I of Target 2035, an international federation of biomedical scientists from the public and private sectors that aims to address this gap by developing and applying new technologies towards generating specific pharmacological modulators for all human proteins.
